California Setting Stage for Crackdown on Dubious Stem Cell Clinics
By David Jensen,
California Stem Cell Report
| 12. 09. 2018
The California stem cell agency, state regulators and lawmakers are taking aim at the more than 100 dubious, unregulated "stem cell" clinics now operating in the Golden State.
The goal is to curb clinics that are using what they describe as stem cells in treatments costing thousands of dollars but that have not been tested scientifically.Lawsuits have been filed around the country alleging damage to patients that includes blindness.
Art Torres, vice chairman of the state stem cell agency, is now working with lawmakers to formulate legislation that is expected to be introduced by the end of January.
At the same time, the State Medical Board, which licenses and regulates physicians, has chartered a task force to look into the the growing business.
Earlier this fall, Torres told the governing board of the California Institute for Regenerative Medicine (CIRM), as the agency is formally known, that he was engaged with Assemblyman Kevin Mullin, D-San Mateo, on a bill.
Torres, a former state lawmaker, said the legislation is expected to involve certification of clinics by a...
Related Articles
By Alfonso Martinez Arias, Nicolas Rivron, and Naomi Moris, BioNews | 04.20.2026
By George Janes, BioNews | 04.20.2026
New regulations in sperm donation are being implemented by Belgium's Federal Agency for Medicines and Health Products (FAMHP), following revelations regarding the use of sperm carrying a cancer-causing mutation, and widespread breaches of donor limits.
In 2025, it...
By Sriparna Roy, Reuters | 04.23.2026
The U.S. Food and Drug Administration has approved Regeneron’s gene therapy for a rare genetic form of deafness, the company said on Thursday.
This approval, granted under the FDA’s new priority voucher program, marks the introduction of the first gene...
By Fyodor D. Urnov and Sadik H. Kassim, Nature | 04.21.2026
In February, the US Food and Drug Administration (FDA) proposed a radical rethink of how scientists, physicians and manufacturers develop personalized genetic therapies. The regulator’s suggested introduction of a ‘plausible mechanism pathway’ should increase incentives for drug companies to develop...
